Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.35 1.5

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.34

Maxim

1.37

Indicatori cheie
By Trading Economics
Venit	-5.7M -25M
Vânzări	-45K 1.5M
EPS	-0.07
Marjă de profit	-1,671.841
Angajați	116
EBITDA	-2.5M -20M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+653.68% upside

Dividende
By Acuity
Următoarele câștiguri	4 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	35M 451M
Deschiderea anterioară	-0.15
Închiderea anterioară	1.35

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 sept. 2026, 23:51 UTC

ECB President Lagarde's Upcoming Speech on September 9, 2026, Expected to Address Interest Rates and Inflation Amidst Euro Area Economic Uncertainties.

6 sept. 2026, 23:51 UTC

Correlated Moves

Avalanche is trading higher, boosted by strong performance in correlated assets like Ethereum. It is currently 8.96% above its 20-day moving average.

6 sept. 2026, 23:41 UTC

Investors Brace for September 11 CPI Release Amid Rising Inflation Concerns and Economic Uncertainties

6 sept. 2026, 23:41 UTC

Investors Brace for Key CPI Release on September 11, Anticipating Impact on Inflation Trends and Market Dynamics.

6 sept. 2026, 23:41 UTC

U.S. Inflation Rate Expected to Stabilize at 3.4% Amid Market Caution and Potential Fed Interest Rate Hikes

6 sept. 2026, 23:41 UTC

U.S. Core Inflation Rate Expected at 2.4% Amid Rising Market Volatility and Anticipated Fed Rate Hike Discussions

6 sept. 2026, 23:41 UTC

Core Inflation Rate Expected to Rise 0.2% in August, Sparking Optimism Among Traders Ahead of September Release

6 sept. 2026, 23:41 UTC

U.S. Inflation Rate Expected to Rise by 0.4% in August, Heightening Concerns Over Interest Rate Hikes Amid Strong Job Growth

6 sept. 2026, 23:31 UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Inflation Concerns and Potential Fed Rate Hikes

6 sept. 2026, 23:21 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% Amid Caution Over Potential Fed Rate Hikes

6 sept. 2026, 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid Investor Anticipation of Economic Catalysts

6 sept. 2026, 22:41 UTC

Australia's Westpac Consumer Confidence report set for September 8, 2026, shows cautious optimism amid inflation concerns and rising investor confidence.

6 sept. 2026, 22:31 UTC

Mexican Inflation Rate Expected to Continue Declining Trend Ahead of September 9 Release, Boosting Market Optimism.

6 sept. 2026, 22:31 UTC

Mexico's Inflation Rate Release on September 9, 2026 Expected to Influence Market Dynamics Amid Global Economic Sentiment.

6 sept. 2026, 22:31 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid mixed market expectations and rising optimism following increased buying activity.

6 sept. 2026, 22:21 UTC

MBA 30-Year Mortgage Rate Release on September 9, 2026, Expected to Show Continued Upward Pressure Amid Inflation and Fed Policy Concerns.

6 sept. 2026, 22:11 UTC

Brazil's Central Bank to Provide Key Insights on Monetary Policy Direction in Upcoming Interest Rate Readout Amid Market Uncertainty

6 sept. 2026, 22:01 UTC

Japan's GDP Growth Forecasted at +1.1% for Q2 2026 Amid Cautious Optimism in Economic Recovery

6 sept. 2026, 22:01 UTC

Japan's GDP Growth Rate Expected at +0.4% Amidst Rising Market Confidence and Global Economic Discussions

6 sept. 2026, 21:51 UTC

Turkey's Central Bank Expected to Maintain 37% Interest Rate Amid Inflation Concerns Ahead of September Decision.

6 sept. 2026, 21:51 UTC

UK Housing Market Faces Continued Pressure as RICS House Price Balance Forecast Improves Slightly to -0.28% Amid Weak Buyer Demand

6 sept. 2026, 21:31 UTC

South Korea's August 2026 unemployment rate release on September 8 sparks cautious optimism amid recent job gains and inflationary pressures.

6 sept. 2026, 21:11 UTC

UK Retail Sales Monitor YoY for August 2026 Expected to Show Modest 1.2% Increase Amid Cautious Consumer Sentiment and Economic Challenges

6 sept. 2026, 21:01 UTC

Spain's Consumer Confidence report on September 8, 2026, shows rising optimism with an index increase to 81.2 amid recovering market sentiment and geopolitical concerns.

6 sept. 2026, 21:01 UTC

Cautious Market Sentiment Ahead of South Africa's Q2 GDP Growth Rate Release Amid Global Economic Fluctuations

6 sept. 2026, 21:01 UTC

South Africa's GDP Growth Rate Release on September 8, 2026 Sparks Market Optimism Amid Global Economic Factors.

6 sept. 2026, 20:21 UTC

Japan's Current Account data set for release on September 7, 2026, forecasts a surplus of JPY 2.87 trillion amid cautious investor sentiment due to historical volatility in outcomes.

6 sept. 2026, 19:01 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Expected to Reflect Volatile U.S. Inventory Trends Amid Geopolitical Tensions and OPEC+ Production Stability.

6 sept. 2026, 18:51 UTC

Italy's Industrial Production Expected to Rise 0.3% in July Amidst Recent Declines and Economic Concerns

6 sept. 2026, 18:31 UTC

France's Industrial Production Expected to Rise 0.3% in July Amid Economic Uncertainty

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

653.68% sus

Prognoză pe 12 luni

Medie 10.25 USD 653.68%

Maxim 12 USD

Minim 8 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.